The prognosis of breast cancer patients depends mainly on their stage and type of pathology, combined with their immunohistochemical parameters. Immunohistochemical indicators usually include ER and PR, ER is estrogen receptor and PR is progesterone receptor. If any of the two is positive, then in addition to chemotherapy and radiotherapy, endocrine therapy can be added to reduce the metastasis and recurrence of breast cancer tumors after surgery. Therefore, the prognosis of breast cancer patients usually depends on the stage, that is, the size of the tumor, the presence of lymph node metastasis, the presence of distant metastasis, and very importantly, the immunohistochemical results, including estrogen receptor, progesterone receptor and whether HER-2 is positive. If HER-2 is positive, treatment with the molecularly targeted drug Herceptin can be used to improve the cure rate.